Furthermore, in patients with ulcerative colitis elevated levels of IL-18 inversely correlate with CYLD expression, suggesting that CYLD deubiquitination of NLRP6 could be a new therapeutic approach for treating intestinal inflammation62–64. This evidence concerns the gene CYLD and ulcerative colitis.